Literature DB >> 12574224

Hyperthyroidism is associated with suppressed circulating ghrelin levels.

Anne Lene Dalkjaer Riis1, Troels Krarup Hansen, Niels Møller, Jørgen Weeke, Jens Otto Lunde Jørgensen.   

Abstract

Ghrelin stimulates GH secretion as well as appetite and food intake. To explore whether ghrelin is involved in the regulation of appetite and body weight in hyperthyroidism, circulating ghrelin levels were measured in nine hyperthyroid patients before and after medical treatment and compared with those in eight healthy control subjects. All participants were studied in the postabsorptive state and during a 3-h euglycemic hyperinsulinemic clamp. Before treatment the patients had 3- to 5-fold elevations of T(3), and during treatment the patients gained 5 kg of body weight. Ghrelin levels were decreased in hyperthyroidism both in the fasting state (hyperthyroid, 1080 +/- 195 pg/ml; euthyroid, 1480 +/- 215 pg/ml; P = 0.03) and during clamp (hyperthyroid, 833 +/- 150 pg/ml; euthyroid, 1210 +/- 180 pg/m; P = 0.02). After treatment, ghrelin levels did not differ from those in control subjects. In all three study groups the clamp significantly reduced ghrelin levels compared with fasting levels. In conclusion, ghrelin levels are reduced in hyperthyroidism and become normalized by medical antithyroid treatment. Hyperinsulinemia suppresses ghrelin regardless of thyroid status. Ghrelin is not a primary stimulator of appetite and food intake in hyperthyroidism, and the mechanisms underlying the suppressive effect of hyperthyroidism on ghrelin secretion remain unclear.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574224     DOI: 10.1210/jc.2002-021302

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Ghrelin and the metabolic balance.

Authors:  O Ukkola
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

2.  Ghrelin localization in rat and human thyroid and parathyroid glands and tumours.

Authors:  Kawtar Raghay; Tomás García-Caballero; Rubén Nogueiras; Gérard Morel; Andrés Beiras; Carlos Diéguez; Rosalía Gallego
Journal:  Histochem Cell Biol       Date:  2005-09-27       Impact factor: 4.304

3.  Serum apelin levels in patients with thyroid dysfunction.

Authors:  Ali Gürel; Akif Doğantekin; Yusuf Özkan; Süleyman Aydın
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Hunger-satiety signals in patients with Graves' thyrotoxicosis before, during, and after long-term pharmacological treatment.

Authors:  Sven Röjdmark; Jan Calissendorff; Olle Danielsson; Kerstin Brismar
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

Review 5.  Interrelationships between ghrelin, insulin and glucose homeostasis: Physiological relevance.

Authors:  François Chabot; Alexandre Caron; Mathieu Laplante; David H St-Pierre
Journal:  World J Diabetes       Date:  2014-06-15

6.  Effect of Helicobacter pylori eradication on serum ghrelin and obestatin levels.

Authors:  Celal Ulasoglu; Banu Isbilen; Levent Doganay; Filiz Ozen; Safak Kiziltas; Ilyas Tuncer
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

7.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

8.  Not insulin but insulin sensitivity, leptin, and cortisol are major factors regulating serum acylated ghrelin level in healthy women.

Authors:  A Kempa; B Krzyzanowska-Swiniarska; T Miazgowski; K Pilarska
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

9.  Expression of obestatin and ghrelin in papillary thyroid carcinoma.

Authors:  Aziz Karaoglu; Suleyman Aydin; Adile F Dagli; David E Cummings; Ibrahim H Ozercan; Halit Canatan; Yusuf Ozkan
Journal:  Mol Cell Biochem       Date:  2008-11-28       Impact factor: 3.396

10.  Exercise, hormones, and body temperature. regulation and action of GH during exercise.

Authors:  J O L Jørgensen; M Krag; J Kanaley; J Møller; T K Hansen; N Møller; J S Christiansen; H Orskov
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.